Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide Dose Finding in Type 2 Diabetes
NCT00696657Phase 2Completed
- Sponsor
- Novo Nordisk
- Start
- Jun 2008
- Primary completion
- Feb 2009
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 14
01
Overview
Phase 2, randomised, double-blind trial of semaglutide in type 2 diabetes mellitus (T2DM) (14 arms), sponsored by Novo Nordisk. Primary endpoint: Glycated Hemoglobin A1c at 12 weeks. Started Jun 2008; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00696657.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00696657.